Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2005

View Archived Issues

Neuropeptide Y Y2 antagonist effective in rats with ethanol dependence

Neuroprotective effects of thiazolidinediones in a preclinical model of stroke

RP-101 reported to improve survival in patients with advanced pancreatic cancer

Phase II data on the benefits of PT-141 in female sexual dysfunction

Putative antidepressant LY-367265 inhibits glutamate release in rat cortex

Update on the efficacy of rasburicase in the prevention of hyperuricemia in cancer patients

Ondansetron improves auditory gating in schizophrenic patients

Positive findings in phase II study of ProMune plus chemotherapy in NSCLC

ReceptoPharm plans phase IIb/III study of RPI-78M in adrenomyeloneuropathy

Phase IIb/III DIAS2 study begins for desmoteplase in acute ischemic stroke

Boehringer Ingelheim discontinues development of bivatuzumab mertansine

Adderall XR sales suspended in Canada

Pharmacokinetic study of TRANSDUR-based sufentanil patch completes dosing

Phase II study of Durect's postoperative pain relief depot product progresses

Positive phase III results for Nuvigil

XP-13512 enters phase IIb study for restless legs syndrome

SPA agreement for phase III study of Cloretazine in relapsed AML

Vical completes SPA for Allovectin-7

SOT-107 receives Japanese orphan drug status

Three series of chemokine CCR4 receptor modulators claimed by AstraZeneca

New anticoagulant agents reported by Bristol-Myers Squibb

Aventis imparts new tubulin polymerization inhibitors for cancer therapy

Novel antiinflammatory chalcones patented by AtheroGenics

Bristol-Myers Squibb patent covers new antiinflammatory agents

Metabotropic glutamate (mGluR5) receptor antagonists described in patent literature

First anti-HIV dual CCR5/CXCR4 antagonist described / News in Context

New title added to the Drug R&D Backgrounders topic list - Osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...